AstraZeneca PLC (AZN)vsTwist Bioscience Corp (TWST)
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
TWST
Twist Bioscience Corp
$115.67
+6.04%
HEALTHCARE · Cap: $5.70B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 14886% more annual revenue ($61.37B vs $409.48M). AZN leads profitability with a 17.0% profit margin vs -19.9%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
TWST
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Margin of Safety
+57.9%
Fair Value
$117.77
Current Price
$115.67
$2.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
19.3% revenue growth
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Trading at 15.8x book value
0.0% earnings growth
ROE of -17.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : TWST
The strongest argument for TWST centers on Debt/Equity, Revenue Growth. Revenue growth of 19.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : TWST
The primary concerns for TWST are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while TWST is a growth play — different risk/reward profiles.
TWST carries more volatility with a beta of 2.12 — expect wider price swings.
TWST is growing revenue faster at 19.3% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 26/100), backed by strong 17.0% margins. TWST offers better value entry with a 57.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Twist Bioscience Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?